Chairman changes chair

Chairman changes chair

29.01.2013 - Instead of renewing his contract, Bayer Healthcare AG Chairman Jörg Reinhardt (56) is seeking new opportunities.

The member of Bayer‘s Executive Council is standing for election as Director and non-executive Chairman at Novartis, and hopes to follow Daniel Vasella in the post. Board member Wolfgang Plischke will take over Reinhardt's role at Bayer. The pharma executive is returning to his roots. He began his career with Sandoz in 1981, which became part of Novartis 15 years later. In 2008, Reinhardt became COO of the Novartis Group, and in 2012 he was appointed to the Board of Lonza Group AG in Basel.

Photo: Bayer HealthCare

02.07.2013 Rob Duchateau, private lecturer at the University of Eindhoven (Netherlands) and academic head of SABICO, has received this year’s DPI Award.

At the end of June, the Dutch Polymer Institute Invention Award has been handed at the biennial conference of the European Polymer Federation (EPF) in Pisa, Italy. The Jury underlined Duchateau’s merits in the field of polymer applications and properties as an outstanding example for connection of academic knowledge with industrial application. In order to promote the significance of inventions, the DPI Invention Award is presented every two years to a scientist from the DPI network. The number of inventions and the industrial relevance are the most important criteria for granting. 

09.07.2013 Orexo AB has named Henrik Juuel as new Executive Vice President and CFO. According to the company, Juuel brings in extensive experience from senior managements positions within the life science industry, including positions as CFO for NNE Pharmaplan and GN Resound.

“His experience from financial management of international commercial operations will be important for the success of Orexo AB, as our company continues expanding,” says Nikolaj Sørensen, President and CEO of Orexo. Henrik Juuel succeeds Carl-Johan Blomberg, who will leave Orexo after successful two-year tenure.

21.06.2013 The Stratified Medicine Scotland Innovation Centre will kick off in 2015 with a global life science entrepreneur at its helm. Dr David U’Prichard was selected as the first Chairman of the £20m Innovation Centre.

U’Prichard is currently president of US-based pharmaceutical and biotechnology consulting firm Druid Consulting LLC. He is also the chief scientific officer at BioMotiv LLC and a member of the corporate boards of Life Technologies Inc (now ThermoFisher Scientific), Cyclacel Inc, and Iroko Pharmaceuticals LLC. Originally from Rothesay (Scotland), but now based in Philadelphia, the new chairman has pharma-cology degrees from the University of Glasgow and the University of Kansas. He has held academic appointments at Northwestern University, Johns Hopkins University and the University of Penn-sylvania, and is an Honorary Professor at the University of Glasgow. U’Prichard has authored more than 100 publications and is a member of various editorial boards.

23.07.2013 The BioIndustry Association (BIA) board has elected Edward Hodgkin as its new Chairman, effective as of 30 October 2013. He succeeds Tim Edwards, who will remain a member of the BIA Board.

Hodgkin is a pharmaceutical/biotech executive with 22 years of experience in Big Pharma, research services and start-up bio-tech ventures. He has been the BIA's Non-executive Director since 2010. The chemist is a partner at Syncona Partners, where he leads new life science ventures. Prior to joining Syncona in April 2013, he was CEO of Biotica Technology Ltd. 

31.07.2013 British Abcam plc (Cambridge) has named Alan Hirzel as Chief Marketing Officer in an attempt to boost future growth in the protein research tool market. Alan will take responsibility for Abcam’s branding, product portfolio and online consumer offering.

He has more than 20 years of global business and leadership experience. Prior to joining Abcam, he spent 14 years with Bain & Company, served at The Social Business Trust, and has recently been appointed to the board of the UK National Citizen Service.

06.08.2013 Imperial Innovations Group plc has appointed Russ Cummings as its new CEO to replace Susan Searle, who has stepped down. Cummings has been the group's Chief Investment Officer and a director since its flotation in 2006.

Prior to his career at the technology commercialisation and investment group, the mechanical engineer worked at Scottish Equity Partners as a director in the Information Technology Group, as well as at 3i Group and with Royce Motors.

09.07.2013 Nicholas Michael has joined British RSSL as Senior Scientist to head up the company's protein characterisation services.

With 10 years' experience in mass spectrometry and HPLC, Nicholas has previously worked at Cancer Research and Lonza Biologics. Protein characterisation, including glycosylation profiling and impurity profiling, is one of several GMP services that RSSL offers to the pharmaceutical/bio-pharma industry.

09.07.2013 Protuduese API specialist Hovione has appointed Justin Hughey to lead the Particle Design sciences at its site in New Jersey.

The pharmacist is an acknowledged expert in the field of solubilization including the creation of amorphous solid dispersions with emphasis on Hot Melt Extrusion.  Hughey comes in from Austin-based cpmpany Enavail where he was Director of Research. His pharmaceutical development experience extends to particle engineering technologies for pulmonary delivery as well as controlled and immediate release solid oral dosage forms. 

26.06.2013 Ute Kilger, a partner with Boehmert & Boehmert in Berlin, Germany, was honored for her expertise in Biotechnology Law by Best Lawyers on June 11.

 She works heavily in European patents and trademarks . The attorneys named to Best Lawyers have been recognized by their peers in the legal industry for their professional excellence in their practice areas. Kilger studied chemistry at the University of Merseburg, and completed her doctorate in biochemistry at the Freie Universität Berlin. Following her doctorate, she embarked on her training as a European patent attorney in the patent department of Boehringer Mannheim GmbH. Since August 2009, she has worked as a partner in the areas of biology/chemistry/pharmaceuticals at the Berlin office of Boehmert & Boehmert. She frequently lectures on IP protection at the University of Potsdam and at the Charite-Universitätsmedizin Berlin. 

18.06.2013 European Bioplastics elected François de Bie to chair the lobby organisation’s new board.

Members include Maria-Giovanna Vetere (NatureWorks), Jürgen Keck (BASF), Peter Brunk (Biotec), Rainer Schweda (Braskem), and Johnny Pallot (Roquette). De Bie, who will succeed the association's former Chairman, Andy Sweetman from Innovia Films, is currently marketing manager of Dutch PLA and succinic acid producer Purac, a subsidiary of CSM N.V. Previously, he worked with Sabic Innovative Plastics and GE Plastics.

Vorherige Seite4/8Nächste Seite


Current issue

All issues

Product of the week


Stock list

All quotes


  • ARGEN-X (B)14.20 EUR5.19%
  • MAGFORCE (D)4.71 EUR4.43%
  • DIAMYD MEDICAL -B- (S)7.20 SEK4.35%


  • BIONOR PHARMA (N)0.41 NOK-6.82%
  • PHOTOCURE (N)41.00 NOK-6.61%
  • SAREUM HOLDINGS (UK)0.74 GBP-5.13%


  • KARO BIO (S)43.10 SEK30.6%
  • MOLMED (I)0.42 EUR27.3%


  • BIONOR PHARMA (N)0.41 NOK-28.1%
  • WILEX (D)1.46 EUR-13.6%


  • NICOX (F)10.29 EUR430.4%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1085.00 DKK81.6%


  • BB BIOTECH (D)44.30 EUR-82.9%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)92.00 GBP-73.1%

No liability assumed, Date: 30.08.2016


All Events